Journal of Antimicrobial Chemotherapy (1999) 44, 661-667
© 1999 The British Society for Antimicrobial Chemotherapy
Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin
1 Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust and University of Bristol, Department of Medical Microbiology, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK 2 Faculty of Applied Sciences, University of the West of England, Frenchay, Bristol BS16 1QY, UK
The pharmacodynamics of ciprofloxacin were explored in an in-vitro continuous bacterial culture model of infection, by simulating two oral dosing regimens; 0.5 g 12-hourly (bd) and 1 g 24-hourly (od). Three strains of Escherichia coli (ciprofloxacin MICs 0.03, 0.5 and 2 mg/L); two strains of Pseudomonas aeruginosa (MICs 0.09 and 1.5 mg/L), two strains of Staphylococcus aureus (MICs 0.12 and 1 mg/L) and two strains of Streptococcus pneumoniae (MICs 0.5 and 2 mg/L) were used. Three pharmacodynamic parameters, T > MIC, Cmax/MIC and AUC/MIC (T = time, Cmax = peak serum concentration, AUC = area under the curve), were compared with area under the bacterial-kill curve (AUBKC) (after transformation of the AUBKC) using a simple Emax or sigmoidal Emax model. AUBKC was taken to be the main antibacterial effect measure. The models were compared by inspection of residuals and Akaike information criterion. Emax models adequately described the relationship between AUC/MIC and AUBKC and between Cmax/MIC and AUBKC, but not between T> MIC and AUBKC. All three pharmacodynamic parameters are related to each other but multiple regression analysis indicated that AUC/MIC was the best individual predictor of AUBKC. Despite this, comparison of od and bd regimens indicates some advantage to od in terms of early antibacterial effect. Serum concentration–time curve shape has some importance in determining antibacterial effect. These data indicate that for ciprofloxacin AUC/MIC ratio is not the sole determinant of antibacterial effect.
* Corresponding author. Tel:+44-117-959-5654; Fax+44-117-959-3154; E-mail: bowker_k{at}Southmead.swest.nhs.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. E. Bowker, A. R. Noel, and A. P. MacGowan Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection J. Antimicrob. Chemother., November 1, 2009; 64(5): 1044 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. B. Ba, C. Arpin, C. Vidaillac, A. Chausse, M.-C. Saux, and C. Quentin Activity of Gatifloxacin in an In Vitro Pharmacokinetic-Pharmacodynamic Model against Staphylococcus aureus Strains either Susceptible to Ciprofloxacin or Exhibiting Various Levels and Mechanisms of Ciprofloxacin Resistance. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1931 - 1936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
|
|
C. N. H. Marques, V. C. Salisbury, J. Greenman, K. E. Bowker, and S. M. Nelson Discrepancy between viable counts and light output as viability measurements, following ciprofloxacin challenge of self-bioluminescent Pseudomonas aeruginosa biofilms J. Antimicrob. Chemother., October 1, 2005; 56(4): 665 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takei, Y. Yamaguchi, H. Fukuda, M. Yasuda, and T. Deguchi Cultivation of Neisseria gonorrhoeae in Liquid Media and Determination of Its In Vitro Susceptibilities to Quinolones J. Clin. Microbiol., September 1, 2005; 43(9): 4321 - 4327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Regoes, C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3670 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Ba, H. Feghali, C. Arpin, M.-C. Saux, and C. Quentin Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic Model Antimicrob. Agents Chemother., March 1, 2004; 48(3): 946 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Zelenitsky, R. E. Ariano, H. Iacovides, S. Sun, and G. K. M. Harding AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model J. Antimicrob. Chemother., April 1, 2003; 51(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. MacGowan, C. A. Rogers, H. A. Holt, M. Wootton, and K. E. Bowker Pharmacodynamics of Gemifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model of Infection Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2916 - 2921. [Abstract] [Full Text]
|
|
|
|
|
|
A. MacGowan, C. Rogers, and K. Bowker The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens J. Antimicrob. Chemother., August 1, 2000; 46(2): 163 - 170. [Full Text] [PDF]
|
|